GAIN TO SOCIETY FROM RHEUMATOID ARTHRITIS TREATMENT: DATA FROM RANDOMIZED TRIALS

被引：0
作者：
Kavanaugh, A. [1 ]
机构：
[1] Univ Calif San Diego, San Diego, CA 92103 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2013年 / 71卷
关键词：
COST-EFFECTIVENESS;
D O I：
10.1136/annrheumdis-2012-eular.1479
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2 / 2
页数：1
相关论文
共 6 条
[1]   Cost-effectiveness analysis: Out of touch with clinical reality? [J].
Maetzel, A .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2005, 53 (01) :3-4
[2]  
SOLOMON D, 2004, INT J ADV RHEUMATOL, V2, P91
[3]   The effect of biological agents on work participation in rheumatoid arthritis patients: a systematic review [J].
ter Wee, M. M. ;
Lems, W. F. ;
Usan, H. ;
Gulpen, A. ;
Boonen, A. .
ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (02) :161-171
[4]   Methodological issues when measuring paid productivity loss in patients with arthritis using biologic therapies: an overview of the literature [J].
Verstappen, Suzanne M. M. ;
Fautrel, Bruno ;
Dadoun, Sabrina ;
Symmons, Deborah P. M. ;
Boonen, Annelies .
RHEUMATOLOGY, 2012, 51 (02) :216-229
[5]   Do rheumatology cost-effectiveness analyses make sense? [J].
Wolfe, F ;
Michaud, K ;
Pincus, T .
RHEUMATOLOGY, 2004, 43 (01) :4-6
[6]  
Wong JB, 2004, CLIN EXP RHEUMATOL, V22, pS65
1